To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or email email@example.com.
|KD025||Pivotal||KD025-213||Chronic graft-versus-host disease (cGVHD) after at least 2 prior lines of systemic therapy|
|KD025||Phase 2||KD025-208||Chronic graft-versus-host disease (cGVHD) after 1-3 prior lines of systemic therapy|
|KD025||Phase 2||KD025-209||Diffuse Cutaneous Systemic Sclerosis (SSc)|
|KD025||Phase 2||KD025-207||Idiopathic Pulmonary Fibrosis (IPF)|
|Tesevatinib||Phase 2||KD019-211||Autosomal Dominant Polycystic Kidney (ADPKD)|
At this time, Kadmon’s investigational therapies are not available on an expanded access or right-to-try basis. In the event Kadmon decides to consider expanded access or right-to-try use, the Company will evaluate and respond to each request that it receives on a case-by-case basis. For more information on our investigational therapies and ongoing clinical trials, please visit Kadmon.com/clinicalpipeline or clinicaltrials.gov.